Venus Concept

Venus Concept, Inc. develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related practice enhancement services. Its product portfolio consists of aesthetic device platforms which includes venus versa, venus legacy, venus velocity, venus fiore, venus viva, venus freeze plus, and venus bliss. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Venus Concept surpasses revenue expectations in Q1 2024 earnings call

Venus Concept's Q1 2024 performance showed resilience with revenue exceeding expectations despite challenges. Strategic initiatives to exit unprofitable markets and focus on cash system sales led to improved financial metrics. The company's progress in key initiatives and financial improvements demonstrate a commitment to long-term growth and stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept (VERO) delivered earnings and revenue surprises of -100% and 9.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Venus Concept (VERO) Reports Q2 Loss, Misses Revenue Estimates

TORONTO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2022.

Venus Concept Announces Second Quarter of Fiscal Year 2022 Financial Results; Updates Fiscal Year 2022 Revenue Guidance

TORONTO, June 30, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2022 financial results will be released before the market opens on Friday, August 12, 2022.

Venus Concept to Release Second Quarter of Fiscal Year 2022 Financial Results on August 12, 2022

Venus Concept Inc. (NASDAQ:VERO ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Dom Serafino - CEO Domenic Penna - CFO Ross Portaro - President of Global Sales Conference Call Participants Marie Thibault - BTIG Jeffrey Cohen - Ladenburg Thalmann Jon Block - Stifel Anthony Vendetti - Maxim Group Operator Please standby. Good day, ladies and gentlemen and welcome to the First Quarter 2022 Earnings Conference Call for Venus Concept Inc. At this time, all participants have been placed on a listen-only mode.

Venus Concept Inc. (VERO) CEO Dom Serafino on Q1 2022 Results - Earnings Call Transcript

Venus Concept (VERO) delivered earnings and revenue surprises of -30% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Venus Concept (VERO) Reports Q1 Loss, Misses Revenue Estimates

TORONTO, May 12, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2022.

Venus Concept Announces First Quarter of Fiscal Year 2022 Financial Results; Reaffirms Fiscal Year 2022 Revenue Guidance

Clearance Expands Indications for Use to Include Non-Invasive Lipolysis of the Back and Thighs and Increases Maximum Energy Output to 150 Watts Clearance Expands Indications for Use to Include Non-Invasive Lipolysis of the Back and Thighs and Increases Maximum Energy Output to 150 Watts

Venus Concept Receives New FDA 510(k) Clearance for Venus BlissMAX

TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that the first patient has been treated in a U.S. Investigational Device Exemption (IDE) clinical study evaluating the safety and efficacy of the Company's Aime™ next generation robotic technology for the treatment of moderate to severe facial wrinkles. Aime is a robotic platform designed to provide micro-coring for medical aesthetic applications.

Venus Concept Announces First Patient Treatment in Study Evaluating the Safety and Efficacy of Aime™ Next Generation Robotic Technology for the Treatment of Moderate to Severe Facial Wrinkles

TORONTO, April 04, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2022 financial results will be released after the market closes on Thursday, May 12, 2022.

Venus Concept to Release First Quarter of Fiscal Year 2022 Financial Results on May 12, 2022

TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced it has submitted a 510(k) premarket notification (“510(k)”) to the U.S. Food and Drug Administration ("FDA"), which is intended to obtain a general clinical indication related to the use of its Aime™ next generation robotic technology for tissue excision and skin resurfacing. Aime is a robotic platform designed to provide micro-coring for medical aesthetic applications.

Venus Concept Submits FDA 510(k) Related to the Use of its Aime™ Next Generation Robotic Technology for Tissue Excision and Skin Resurfacing

Venus Concept Inc. (VERO) CEO Dom Serafino on Q4 2021 Results - Earnings Call Transcript

Venus Concept (VERO) delivered earnings and revenue surprises of 33.33% and 0.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Venus Concept (VERO) Reports Q4 Loss, Tops Revenue Estimates

TORONTO, March 28, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2021.

Venus Concept Announces Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Revenue Guidance

TORONTO, March 21, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will present at the Maxim Virtual Growth Conference, which is being held virtually from March 28th-30th.

Venus Concept Inc. to Present at the Maxim Virtual Growth Conference on March 28th

TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Venus Concept Inc. to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16th

TORONTO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2022 financial results will be released before the market opens on Monday, March 28, 2022.

Venus Concept to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 28, 2022

TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market the Venus BlissMAX device (“BlissMAX”) in the United States.

Venus Concept Receives FDA 510(k) Clearance of Venus BlissMAX for Non-Invasive Lipolysis of the Abdomen and Flanks, Cellulite Reduction and Muscle Conditioning

TORONTO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today reported preliminary unaudited revenue results for the three months ended December 31, 2021.

Venus Concept Reports Preliminary Revenue Results for Fourth Quarter 2021

Amneal Pharmaceuticals

Accelerate Diagnostics

XpresSpa Group

Insiders are buying these penny stocks during "tax loss season" The post Penny Stocks To Buy Now According To Insiders In December 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Now According To Insiders In December 2021

Venus Concept Inc. (VERO) CEO Dom Serafino on Q3 2021 Results - Earnings Call Transcript

Venus Concept Inc's (NASDAQ: VERO) Q3 sales increased 19% Y/Y to $24.6 million, missing the consensus of $26.43 million. On a sequential basis, the sales declined around 5%.

Venus Concept Stock Down As Q3 Earnings Trail Street Expectations

TORONTO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2021.

Venus Concept Announces Third Quarter and First Nine Months of 2021 Financial Results; Updates Fiscal Year 2021 Revenue Guidance

Venus Concept (VERO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Venus Concept (VERO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

The FDA has given 510(k) clearance to Venus Concept Inc's (NASDAQ: VERO) Venus Freedom device for pain management. Venus Freedom is a noninvasive, non-ablative device with three applicators to deliver non-thermal radiofrequency energy combined with massage and magnetic field pulses.

Venus Concept's Pain Management Device Scores FDA Nod

TORONTO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market the Venus Freedom device in the United States.

News for Venus Concept Stock (VERO)